Modulation of the vasopressin system for the treatment of CNS diseases

Current Opinion in Drug Discovery and Development

Volumn 13, Issue 5, 2010, Pages 538-547

  Ryckmans, Thomas ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Anxiety; arginine vasopressin; AVP; CNS penetration; schizophrenia; stress; V1a; V1b; vasopressin

Indexed keywords

1 [1 [4 (3 ACETAMIDOPROPOXY)BENZOYL] 4 PIPERIDYL] 1,2,3,4 TETRAHYDRO 2 QUINOLINONE; 1 [5 CHLORO 1 (2,4 DIMETHOXYLPHENYLSULFONYL) 2,3 DIHYDRO 3 (2 METHOXYPHENYL) 2 OXO 1H INDOL 3 YL] 4 HYDROXY N,N DIMETHYL 2 PYRROLIDINECARBOXAMIDE; ABT 436; ABT 558; JNJ 17308616; LIXIVAPTAN; SRX 246; SRX 251; UNCLASSIFIED DRUG; VA 111913; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR;

ANXIETY; ANXIETY DISORDER; AUTISM; BEHAVIOR; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DEPRESSION; DRUG RESEARCH; DRUG TARGETING; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; REVIEW; SCHIZOPHRENIA; SOCIAL INTERACTION;

ANIMALS; BEHAVIOR; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DESIGN; HUMANS; LIGANDS; MOLECULAR STRUCTURE; RECEPTORS, VASOPRESSIN; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP; VASOPRESSINS;

EID: 77956410161     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Ryckmans T: Advances in vasopressin receptor agonists and antagonists. Ann Rep Med Chem (2009) 44:129-147.
2. Lemmens-Gruber R, Kamyar M: Vasopressin antagonists. Cell Mol Life Sci (2006) 63(15):1766-1779.
3. Serradeil-Le Gal C, Wagnon J, Valette G, Garcia G, Pascal M, Maffrand JP, Le Fur G: Nonpeptide vasopressin receptor antagonists: Development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res (2002) 139: 197-210.
4. Costello-Boerrigter LC, Boerrigter G, Burnett JC Jr: Pharmacology of vasopressin antagonists. Heart Fail Rev (2009) 14(2):75-82.
5. Favory R, Salgado DR, Vincent J-L: Investigational vasopressin receptor modulators in the pipeline. Expert Opin Invest Drugs (2009) 18(8):1119-1131.
6. Veenema AH, Neumann ID: Central vasopressin and oxytocin release: Regulation of complex social behaviors. Prog Brain Res (2008) 170:261-276.
7. Walum H, Westberg L, Henningsson S, Neiderhiser JM, Reiss D, Igl W, Ganiban JM, Spotts EL, Pedersen NL, Eriksson E, Lichtenstein P: Genetic variation in the vasopressin receptor 1a gene (AVPR1A) associates with pair-bonding behavior in humans. Proc Natl Acad Sci USA (2008) 105(37):14153-14156.
8. Ebstein RP, Israel S, Lerer E, Uzefovsky F, Shalev I, Gritsenko I, Riebold M, Salomon S, Yirmiya N: Arginine vasopressin and oxytocin modulate human social behavior. Ann NY Acad Sci (2009) 1167:87-102.
9. Surget A, Belzung C: Involvement of vasopressin in affective disorders. Eur J Pharmacol (2008) 583(2-3):340-349.
10. Meyer-Lindenberg A, Kolachana B, Gold B, Olsh A, Nicodemus KK, Mattay V, Dean M, Weinberger DR: Genetic variants in AVPR1A linked to autism predict amygdala activation and personality traits in healthy humans. Mol Psychiatry (2009) 14(10):968-975.
11. Bunck M, Czibere L, Horvath C, Graf C, Frank E, Kessler MS, Murgatroyd C, Mller-Myhsok B, Gonik M, Weber P, Ptz B et al: A hypomorphic vasopressin allele prevents anxiety-related behavior. PLoS One (2009) 4(4):e5129.
12. van West D, Del-Favero J, Aulchenko Y, Oswald P, Souery D, Forsgren T, Sluijs S, Bel-Kacem S, Adolfsson R, Mendlewicz J, Van Duijn C et al: A major SNP haplotype of the arginine vasopressin 1b receptor protects against recurrent major depression. Mol Psychiatry (2004) 9(3):287-292.
13. Insel TR: The challenge of translation in social neuroscience: A review of oxytocin, vasopressin, and affiliative behavior. Neuron (2010) 65(6):768-779.
14. Thompson RR, George K, Walton JC, Orr SP, Benson J: Sex-specific influences of vasopressin on human social communication. Proc Natl Acad Sci USA (2006) 103(20):7889-7894.
15. Maggio ET: Intravail: Highly effective intranasal delivery of peptide and protein drugs. Expert Opin Drug Deliv (2006) 3(4): 529-539.
16. Bosch OJ, Neumann ID: Brain vasopressin is an important regulator of maternal behavior independent of dams' trait anxiety. Proc Natl Acad Sci USA (2008) 105(44):17139-17144.
17. Cilia J, Gartlon JE, Shilliam C, Dawson LA, Moore SH, Jones DN: Further neurochemical and behavioural investigation of Brattleboro rats as a putative model of schizophrenia. J Psychopharmacol (2010) 24(3):407-419.
18. Frank E, Landgraf R: The vasopressin system - From antidiuresis to psychopathology. Eur J Pharmacol (2008) 583 (2-3):226-242.
19. Winslow JT, Hastings N, Carter CS, Harbaugh CR, Insel TR: A role for central vasopressin in pair bonding in monogamous prairie voles. Nature (1993) 365(6446):545-548.
20. Lim MM, Wang Z, Olazábal DE, Ren X, Terwilliger EF, Young LJ: Enhanced partner preference in a promiscuous species by manipulating the expression of a single gene. Nature (2004) 429(6993):754-757.
21. Lim MM, Hammock EA, Young LJ: The role of vasopressin in the genetic and neural regulation of monogamy. J Neuroendocrinol (2004) 16(4):325-332.
22. Nephew BC, Byrnes EM, Bridges RS: Vasopressin mediates enhanced offspring protection in multiparous rats. Neuropharmacology (2009) 58(1):102-106.
23. Tobin VA, Hashimoto H, Wacker DW, Takayanagi Y, Langnaese K, Caquineau C, Noack J, Landgraf R, Onaka T, Leng G, Meddle SL et al: An intrinsic vasopressin system in the olfactory bulb is involved in social recognition. Nature (2010) 464(7287):413-417.
24. Bleickardt CJ, Mullins DE, MacSweeney CP, Werner BJ, Pond AJ, Guzzi MF, Martin FDC, Varty GB, Hodgson RA: Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior. Psychopharmacology (2009) 202(4): 711-718.
25. Simon NG, Guillon C, Fabio K, Heindel ND, Lu SF, Miller M, Ferris CF, Brownstein MJ, Garripa C, Koppel GA: Vasopressin antagonists as anxiolytics and antidepressants: Recent developments. Recent Pat CNS Drug Discov (2008) 3(2):77-93.
26. Ferris CF, Lu SF, Messenger T, Guillon CD, Heindel N, Miller M, Koppel G, Robert Bruns F, Simon NG: Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior. Pharmacol Biochem Behav (2006) 83(2):169-174.
27. Guillon CD, Koppel GA, Brownstein MJ, Chaney MO, Ferris CF, Lu SF, Fabio KM, Miller MJ, Heindel ND, Hunden DC, Cooper RD et al: Azetidinones as vasopressin V1a antagonists. Bioorg Med Chem (2007) 15(5):2054-2080.
28. Ferris CF, Stolberg T, Kulkarni P, Murugavel M, Blanchard R, Blanchard DC, Febo M, Brevard M, Simon NG: Imaging the neural circuitry and chemical control of aggressive motivation. BMC Neurosci (2008) 9:111.
29. Pipeline: Azevan Pharmaceuticals Inc, Bethlehem, PA, USA 2010). www.azevan.com/pipeline/default.asp
30. Ukkola LT, Onkamo P, Raijas P, Karma K, Jrvel I: Musical aptitude is associated with AVPR1A-haplotypes. PLoS One (2009) 4(5):e5534.
31. Heinrichs M, von Dawans B, Domes G: Oxytocin, vasopressin, and human social behavior. Front Neuroendocrinol (2009) 30(4): 548-557.
32. Thomson F, Craighead M: Innovative approaches for the treatment of depression: Targeting the HPA axis. Neurochem Res (2008) 33(4):691-707.
33. Roper J, O'Carroll A-M, Grant EJ, Lolait SJ: The role of the vasopressin V1b receptor in the HPA axis response to acute stress: Molecular and pharmacological studies. Proc Physiol Soc 5, C3 (2007).
34. Duvernoy HM, Risold PY: The circumventricular organs: An atlas of comparative anatomy and vascularization. Brain Res Rev (2007) 56(1):119-147.
35. Schoenberger M, Leggett C, Kim SW, Hooker JM: Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography. Bioorg Med Chem Lett (2010) 20(10):3103-3106.
36. Serradeil-Le Gal C, Raufaste D, Derick S, Blankenstein J, Allen J, Pouzet B, Pascal M, Wagnon J, Ventura MA: Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand. Am J Physiol Regul Integr Comp Physiol (2007) 293(2): R938-R949.
37. Leonard BE: Psychopathology of depression. Drugs Today (2007) 43(10):705-716.
38. Stewart LQ, Roper JA, Scott Young W 3rd, O'Carroll AM, Lolait SJ: The role of the arginine vasopressin AVP1b receptor in the acute neuroendocrine action of antidepressants. Psychoneuroendocrinology (2008) 33(4):405-415.
39. Morphy R: The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J Med Chem (2006) 49(10):2969-2978.
40. Hughes JD, Blagg J, Price DA, Bailey S, Decrescenzo GA, Devraj RV, Ellsworth E, Fobian YM, Gibbs ME, Gilles RW, Greene N et al: Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett (2008) 18(17):4872-4875.
41. Leeson PD, Springthorpe B: The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov (2007) 6(11):881-890.
42. Klon AE: Computational models for central nervous system penetration. Curr Comput-Aided Drug Des (2009) 5(2):71-89.
43. Mensch J, Oyarzabal J, Mackie C, Augustijns P: In vivo, in vitro and in silico methods for small molecule transfer across the blood brain barrier. J Pharm Sci (2009) 98(12):4429-4468.
44. Mehdipour AR, Hamidi M: Brain drug targeting: A computational approach for overcoming blood-brain barrier. Drug Discov Today (2009) 14(21/22):1030-1036.
45. Hitchcock SA, Pennington LD: Structure-brain exposure relationships. J Med Chem (2006) 49(26):7559-7583.
46. Jeffrey P, Summerfield S: Assessment of the blood-brain barrier in CNS drug discovery. Neurobiol Dis (2010) 37(1):33-37.
47. Peters JU, Schnider P, Mattei P, Kansy M: Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent Roche compounds. ChemMedChem (2009) 4(4):680-686.
48. Jain N, Yalkowsky SH: Estimation of the aqueous solubility I: Application to organic nonelectrolytes. J Pharm Sci (2001) 90(2):234-252. (Pubitemid 32158051)
49. Price DA, Blagg J, Jones L, Greene N, Wager T: Physicochemical drug properties associated with in vivo toxicological outcomes: A review. Expert Opin Drug Metab Toxicol (2009) 5(8):921-931.
50. Ferring BV (Andrzej RB, Baxter AJ, Heeney C, Stockley ML, Bryan Roe M, Hudson P, Handy R): Vasopressin V1a antagonists. WO-2006021213 (2006).
51. sanofi-aventis (Couturier C, Foulon L, Serradeil-Legal C, Valette G): 1,3-Dihydro-2H-pyrrolo[3,2-b]pyridin-2-one derivatives, preparation thereof and therapeutic uses thereof. WO-2009133314 (2009).
52. sanofi-aventis (Foulon L, Goullieux L, Pouzet b, Serradeil-Le Gal C, Valette G): Novel 3-aminoalkyl-1,3-dihydro-2H-indol-2-one derivatives, preparation thereof and therapeutic use thereof. WO-2009115685 (2009).
53. Glaxo Wellcome plc (Di Fabio R, Gentile G, Micheli F, Pasquarello A, Pozzan A, Tarsi L, Terreni S, Tonelli F): Pyrrolo[1,2-a]pyrazine derivatives as vasopressin V1b receptor antagonists. WO-2009130231 (2009).
54. Glaxo Wellcome plc (Di Fabio R, Gentile G, Pozzan A, Tarsi L, Terreni S, Tonelli F): Pyrazolo[1,5-a]pyrazine derivatives as antagonists of V1b receptors. WO-2009130232 (2009).
55. Abbott GmbH and Co KG (Braje W, Netz A, Oost T, Wernet W, Unger L, Hornberger W, Lubisch W): Substituted oxindolederivatives and the use thereof for the treatment of vasopressindependent illnesses. WO-2009083559 (2009).
56. Abbott GmbH and Co KG (Netz A, Oost T, Geneste H, Braje W, Wernet W, Unger L, Hornberger W, Lubisch W): Oxindole derivatives and the use thereof as a medication. WO-2009071691 (2009).
57. Abbott GmbH and Co KG (Braje W, Oost T, Netz A, Wernet W, Unger L, Hornberger W, Lubisch W): 5-Halogen-substituted oxindole derivatives and use thereof for treating vasopressin-dependent diseases. WO-2009071689 (2009).
58. Abbott GmbH and Co KG (Braje W, Oost T, Netz A, Wernet W, Unger L, Hornberger W, Lubisch W): 5,6-Disubstituted oxindole-derivatives and use thereof for treating vasopressin-dependent diseases. WO-2009071690 (2009).